Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):9-14. doi: 10.1097/MED.0000000000000034.

New treatment targets for the management of irritable bowel syndrome.

Author information

1
Boston University School of Medicine, Section of Gastroenterology, Boston, Massachusetts, USA.

Abstract

PURPOSE OF REVIEW:

Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are highly prevalent medical conditions that reduce quality of life and represent a substantial economic burden on healthcare cost. Until recently, no specific treatment options were available. This review will provide an update of the most recent randomized clinical trials data showing efficacy and safety of novel, targeted treatment modalities in IBS and CIC with gastrointestinal receptor and ion channel agonists.

RECENT FINDINGS:

Recent discoveries of peptides and small molecules targeting gastrointestinal receptors and ion channels resulted in novel, specific pharmacological therapies of IBS and CIC. The bicyclical fatty acid lubiprostone and the synthetic 14-amino acid peptide linaclotide were identified to selectively activate a Chloride Channel-2 and the Guanylin Cyclase-C receptor, respectively, and demonstrate efficacy in the treatment of IBS with constipation and CIC.

SUMMARY:

Novel molecules including the bicyclical fatty acid lubiprostone and the synthetic 14-amino acid peptide linaclotide represent new treatment modalities for IBS with constipation and CIC with proven efficacy and acceptable side-effect profiles.

PMID:
24300740
DOI:
10.1097/MED.0000000000000034
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center